Vidac Pharma

About

Funding history · 4 rounds · $31.2M total

Headcount over time

Offices

Q&A

What is Vidac Pharma's primary focus?

Vidac Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for oncologic and dermatologic diseases, specifically targeting the VDAC/HK2 system in malignant cells.

What is the status of Vidac Pharma's lead drug, VDA-1102?

Vidac Pharma's lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) and is currently in a Phase 2a clinical trial in Cutaneous T-Cell Lymphoma (CTCL) in Israel.

When did Vidac Pharma go public and on which exchange?

Vidac Pharma went public in March 2023 on the Hamburg Stock Exchange with a valuation of $60,000,000.

What is Vidac Pharma's employee count?

Vidac Pharma has 1-10 employees.

What is the latest development regarding Vidac Pharma's VDA-1275 cancer drug candidate?

In March 2024, Vidac Pharma received a Japanese Patent Office Notice of Allowance for its VDA-1275 cancer drug candidate.

What recent patent was granted to Vidac Pharma in the U.S.?

In September 2024, the U.S. granted Vidac Pharma a patent offering broad protection of the mode of action underlying its oncology drug candidates.

What were the results of Vidac Pharma's VDA-1102 interim Phase 2a data for CTCL?

In January 2024, Vidac Pharma reported positive interim Phase 2a data for its lead asset VDA-1102 in the orphan disease cutaneous T-cell lymphoma (CTCL).

What is Vidac Pharma's total funding raised to date?

Vidac Pharma has raised a total of $9,645,651 across its funding rounds.

Team · 6

Max Herzberg

Founder · Chairperson of the Board, CEO

Oren M. Becker

Board Member

Christian Policard

Board Member

Yochai Richter

Board Member

Joseph Tenne

Board Member

Paul Salama

Vice President of Chemistry, Manufacturing, and Control

Sectors & technology

Highlights

Tags